EX-10.8 10 ea028691901ex10-8.htm VOTING AGREEMENT, DATED APRIL 15, 2026, BY AND AMONG NKGEN BIOTECH, INC., ALPINEBROOK CAPITAL GP I LIMITED, GRAF ACQUISITION PARTNERS IV LLC, NKGEN BIOTECH KOREA CO., LTD. AND PAUL SONG

Exhibit 10.8

 

Execution Version

 

VOTING AGREEMENT

 

THIS VOTING AGREEMENT (this “Agreement”) is made as of April 15, 2026, by and among NKGen Biotech, Inc., a Delaware corporation (the “Company”), AlpineBrook Capital GP I Limited (the “Investor”), Graf Acquisition Partners IV LLC (“Graf Acquisition Partners IV”), NKGen Biotech Korea Co., Ltd. (“NKGen Biotech Korea”), and Paul Song (collectively, with Graf Acquisition Partners IV and NKGen Biotech Korea, the “Stockholders”).

 

RECITALS

 

WHEREAS, contemporaneously with the execution hereof and in reliance hereon, the Company and the Investor are entering into that certain Secured Convertible Loan Agreement of even date herewith (the “Loan Agreement”); and

 

WHEREAS, in order to induce the Investor to enter into the Loan Agreement, the Company and the Stockholders hereby agree as set forth in this Agreement.

 

NOW, THEREFORE, the parties hereby agree as follows:

 

1. Vote to Approve the Increase of Authorized Capital Stock. The Stockholders agree to vote or cause to be voted the greater of (i) all shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”) owned by the Stockholders or (ii) all shares of Common Stock over which the Stockholders have voting control, from time to time and at all times, in whatever manner as shall be necessary to approve an increase in the number of authorized shares of Common Stock such that there are sufficient shares of Common Stock to be issued in connection with the issuance of Consideration Shares (as defined in the Loan Agreement), and there are five (5) times of the shares of Common Stock to be issued in connection with the conversion of the 2026 Secured Convertible Note (as defined in the Loan Agreement), and the exercise of the Warrant (as defined in the Loan Agreement), if so required.

 

2. Successors and Assigns. The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

 

3. Governing Law and Venue. Sections 7.1 and 7.8 of the Loan Agreement shall apply to this Agreement.

 

4. Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via electronic mail (including pdf or any electronic signature complying with the U.S. ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

5. Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.

 

6. Consent Required to Amend, Modify, Terminate or Waive. This Agreement shall not be amended, modified or terminated without the written consent of the Company, Investor, and Stockholders.

 

7. Further Assurances. At any time or from time to time after the date hereof, the parties agree to cooperate with each other, and at the request of any other party, to execute and deliver any further instruments or documents and to take all such further action as the other party may reasonably request in order to carry out the intent of the parties hereunder.

 

8. Costs of Enforcement. If any party to this Agreement seeks to enforce its rights under this Agreement by legal proceedings, the non-prevailing party shall pay all costs and expenses incurred by the prevailing party, including, without limitation, all reasonable attorneys’ fees.

 

[Signature Page Follows Immediately]

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

  THE COMPANY:
   
  NKGen Biotech, Inc.
     
  By: /s/ Paul Y. Song
  Name: Paul Y. Song
  Title: Chief Executive Officer

 

  THE INVESTOR:
   
  AlpineBrook Capital GP I Limited
     
  By: /s/ Hanhan Xu
  Name: Hanhan Xu
  Title: Director

 

  STOCKHOLDER:
   
  Graf Acquisition Partners IV LLC
     
  By: /s/ James Graf
  Name: James Graf
  Title: Managing Member

 

  STOCKHOLDER:
   
  NKGen Biotech Korea Co., Ltd.
     
  By: /s/ Yongman Kim
  Name: Yongman Kim
  Title: President

 

  STOCKHOLDER:
   
  By: /s/ Paul Y. Song
  Name: Paul Y. Song

 

[Signature Page to Voting Agreement]